Stifel Reiterates Buy Rating on AnaptysBio (ANAB)

TD Cowen Reiterates Buy Rating on AnaptysBio (ANAB)

TD Cowen analyst Joseph Thome reiterated a Buy rating on AnaptysBio (NASDAQ: ANAB).

The analyst comments "ANAB released updated data from the Ph. IIb of rosnilimab in RA. Rosnilimab patients that achieved LDA (CDAI10) continued to see benefit in the active... More

H.C. Wainwright Upgrades AnaptysBio (ANAB) to Buy

H.C. Wainwright analyst Emily Bodnar upgraded AnaptysBio (NASDAQ: ANAB) from Neutral to Buy with a price target of $38.00.

The analyst comments "High maintenance of CDAI LDA and ACR responses, including during off-treatment period. Yesterday after market close, AnaptysBio announced anticipated Week 28 data from the Phase 2 rheumatoid arthritis (RA) trial which met its primary endpoint (announced in Feb 2025), evaluating rosnilimab 100 mg Q4W, 400 mg Q4W, or 600 mg Q2W vs placebo in 424 patients. As a reminder, to qualify to continue on treatment beyond the initial induction phase, patients must have had CDAI LDA... More

Anaptysbio (ANAB) Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). In the robust, global 424-patient Phase 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, over a six-month period. Furthermore, responses were then durable for at least two months off drug. Rosnilimab was safe and well... More